RecruitingPhase 4NCT04743518

Impact of Anti-TNF, Vedolizumab and Tofacitinib on Aortic Stiffness, Carotid Intima-media Thickness and Cardiovascular Risk of Patients With Ulcerative Colitis

Sponsor

Centre Hospitalier Universitaire, Amiens

Enrollment

100 participants

Start Date

Feb 2, 2021

Study Type

INTERVENTIONAL

Conditions

Ulcerative Colitis

Summary

An increased risk of cardiovascular (CV) diseases has been observed in patients with inflammatory bowel diseases (IBD). The impact of IBD drugs, such as anti-TNF, anti-integrins or anti-JAK, on the risk of CV events in IBD is remains unknown. Aortic pulse wave velocity (aPWV), a measure of aortic stiffness, and carotid intima media thickness (CIMT) are both predictors of cardiovascular events and are increased in patients with IBD. The investigators aimed to prospectively compare the CV risk, CIMT, arterial stiffness and biomarkers of endothelial dysfunction at baseline and after 3 and 12 months of anti-TNF, vedolizumab and tofacitinib.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study measures how several biologic medications used for ulcerative colitis affect the stiffness of arteries and the thickness of blood vessel walls — both indicators of cardiovascular risk — over time. **You may be eligible if...** - You have ulcerative colitis that has been ongoing for at least 6 months - You are over 18 years old - You are about to start one of these medications: infliximab, adalimumab, golimumab, vedolizumab, or tofacitinib - You have provided written consent **You may NOT be eligible if...** - You recently had a heart attack or stroke - You have diabetes, or your blood pressure or cholesterol medications are not at a stable dose - You are pregnant or breastfeeding - You have already been on one of these medications before Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.